Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 9/20 | 0.54 |
| ▸ | CDK9 | P50750 | 8/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944749 | 1.00 | CCNT1 (0.54) | CCNT1CDK9NTRK1ABL1CDK4 | |
| SCHEMBL12501692 | 0.87 | CDK9 (0.51) | CCNT1CDK9NTRK1CDK4CDK2 | |
| SCHEMBL12501693 | 0.87 | CDK9 (0.51) | CCNT1CDK9NTRK1CDK4CDK2 | |
| SCHEMBL1462840 | 0.87 | CCNT1 (0.57) | CCNT1CDK9 | |
| SCHEMBL12501652 | 0.87 | CDK9 (0.43) | CCNT1CDK9ABL1CDK4CCNA2 | |
| SCHEMBL1947213 | 0.87 | CCNT1 (0.74) | CCNT1 | |
| SCHEMBL1465429 | 0.87 | CCNT1 (0.74) | CCNT1 | |
| SCHEMBL1465512 | 0.87 | CCNT1 (0.74) | CCNT1 | |
| SCHEMBL1462780 | 0.87 | CDK9 (0.47) | CCNT1CDK9ABL1CDK4CCNA2 | |
| SCHEMBL12501715 | 0.86 | MAPK8 (0.44) | CDK9NTRK1ABL1PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101064-A1 | N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101063-A1 | N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | CCNT1 47/4885CDK9 5/4885NTRK1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.